The OPTIMUM Trial
C. Michael Gibson and David Kandzari discuss PCI outcomes among patients at prohibitive risk for CABG.
shuque@crf.org Wed, 06/22/2022 - 13:02
The MASTER DAPT Trial
C. Michael Gibson and Marco Valgimigli discuss dual antiplatelet therapy after coronary stenting in high-bleeding-risk patients.
hdellabella@crf.org Wed, 06/08/2022 - 13:48
The EROSION III Trial
C. Michael Gibson, Haibo Jia, and Jingbo Hou discuss whether OCT guidance could cut stent use in STEMI without plaque rupture.
hdellabella@crf.org Wed, 06/01/2022 - 13:13
The LIFE Trial
C. Michael Gibson and Douglas Mann discuss sacubitril/valsartan in patients with advanced HFrEF.
hdellabella@crf.org Wed, 05/18/2022 - 16:43
PRAGUE 17: LAA Closure vs DOACs
C. Michael Gibson and Pavel Osmancik review 3-year results with LAA closure versus a DOAC for patients with atrial fibrillation.
hdellabella@crf.org Wed, 05/04/2022 - 15:44
MASTER DAPT: High-Risk Patients
C. Michael Gibson and Pieter C. Smits review outcomes in high-bleeding-risk patients also at high risk for thrombotic events who were randomized to abbreviated DAPT.
hdellabella@crf.org Wed, 04/20/2022 - 13:41
The ADAPTABLE Study: Patient-Centered Aspirin
C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt.
hdellabella@crf.org Wed, 04/06/2022 - 14:00
The STRENGTH Study of Omega-3s
C. Michael Gibson and Steven Nissen discuss the link between omega-3 fatty acid levels and MACE in patients with high cardiovascular risk.
hdellabella@crf.org Wed, 03/16/2022 - 13:06
The SWISS-APERO Trial
C. Michael Gibson and Robert Galea discuss Amulet versus Watchman for LAA closure.
hdellabella@crf.org Wed, 03/02/2022 - 13:50
Subscribe to TCTMD Talking Points